Log in
Enquire now
‌

US Patent 7576106 Piperidine derivatives and methods of use

Patent 7576106 was granted and assigned to ChemoCentryx on August, 2009 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Current Assignee
ChemoCentryx
ChemoCentryx
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
75761060
Patent Inventor Names
Edward J. Sullivan0
Penglie Zhang0
Andrew M. K. Pennell0
Wei Chen0
Kevin Lloyd Greenman0
Lianfa Li0
Date of Patent
August 18, 2009
0
Patent Application Number
115802020
Date Filed
October 11, 2006
0
Patent Citations Received
‌
US Patent 11759454 Diazole lactams
‌
US Patent 11744822 Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
Patent Primary Examiner
‌
Rita J Desai
0
Patent abstract

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7576106 Piperidine derivatives and methods of use

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.